Catalent, Inc. (NYSE:CTLT) Receives $55.65 Average Price Target from Brokerages

Catalent, Inc. (NYSE:CTLT) has been assigned an average recommendation of “Hold” from the eleven analysts that are presently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, seven have assigned a hold recommendation and three have issued a buy recommendation on the company. The average 1 year price target among analysts that have covered the stock in the last year is $55.65.

Several analysts have issued reports on the company. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $63.50 target price on shares of Catalent in a research note on Thursday, July 11th. StockNews.com assumed coverage on Catalent in a research note on Thursday. They issued a “sell” rating for the company. Finally, Barclays upped their target price on Catalent from $47.00 to $63.00 and gave the stock an “equal weight” rating in a research note on Friday, June 28th.

Insider Buying and Selling at Catalent

In other Catalent news, insider Ricky Hopson sold 1,401 shares of the business’s stock in a transaction that occurred on Tuesday, June 4th. The stock was sold at an average price of $54.26, for a total value of $76,018.26. Following the completion of the sale, the insider now owns 20,617 shares in the company, valued at $1,118,678.42. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, insider Ricky Hopson sold 1,401 shares of the company’s stock in a transaction that occurred on Tuesday, June 4th. The stock was sold at an average price of $54.26, for a total transaction of $76,018.26. Following the completion of the transaction, the insider now owns 20,617 shares in the company, valued at $1,118,678.42. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO Alessandro Maselli sold 9,088 shares of the company’s stock in a transaction that occurred on Monday, July 29th. The shares were sold at an average price of $58.76, for a total value of $534,010.88. Following the transaction, the chief executive officer now owns 177,521 shares of the company’s stock, valued at approximately $10,431,133.96. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 13,482 shares of company stock worth $779,852. 0.31% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Catalent

Hedge funds and other institutional investors have recently made changes to their positions in the business. Lindbrook Capital LLC raised its holdings in Catalent by 79.4% in the first quarter. Lindbrook Capital LLC now owns 470 shares of the company’s stock worth $27,000 after purchasing an additional 208 shares in the last quarter. GAMMA Investing LLC bought a new position in Catalent in the fourth quarter worth $33,000. Thurston Springer Miller Herd & Titak Inc. bought a new position in Catalent in the second quarter worth $42,000. Rakuten Securities Inc. purchased a new stake in shares of Catalent in the fourth quarter worth $46,000. Finally, Federated Hermes Inc. purchased a new stake in shares of Catalent in the fourth quarter worth $46,000.

Catalent Stock Down 0.3 %

Shares of NYSE CTLT opened at $59.59 on Tuesday. Catalent has a 12 month low of $31.80 and a 12 month high of $60.20. The company has a current ratio of 2.51, a quick ratio of 1.77 and a debt-to-equity ratio of 1.37. The firm has a market capitalization of $10.78 billion, a price-to-earnings ratio of -9.77, a PEG ratio of 2.47 and a beta of 1.16. The business has a 50-day moving average of $56.66 and a 200-day moving average of $56.03.

Catalent (NYSE:CTLT) last issued its quarterly earnings data on Wednesday, May 8th. The company reported ($0.15) EPS for the quarter, missing the consensus estimate of $0.21 by ($0.36). Catalent had a negative return on equity of 2.73% and a negative net margin of 26.61%. The business had revenue of $1.07 billion for the quarter, compared to analysts’ expectations of $1.11 billion. Sell-side analysts expect that Catalent will post -0.17 earnings per share for the current fiscal year.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.